-
Je něco špatně v tomto záznamu ?
Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
HP. Bhattoa, S. Vasikaran, I. Trifonidi, G. Kapoula, G. Lombardi, NR. Jørgensen, R. Pikner, M. Miura, R. Chapurlat, M. Hiligsmann, M. Haarhaus, P. Evenepoel, HS. Jørgensen, M. Herrmann, JM. Kaufman, P. Clark, Ş. Tuzun, N. Al-Daghri, S. Silverman,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, konsensus - konference
- MeSH
- biologické markery krev MeSH
- hodnocení rizik metody MeSH
- inhibitory kostní resorpce terapeutické užití MeSH
- kolagen typu I krev MeSH
- konsensus MeSH
- lidé MeSH
- osteoporotické fraktury prevence a kontrola etiologie MeSH
- osteoporóza * diagnóza patofyziologie farmakoterapie krev terapie MeSH
- peptidové fragmenty krev MeSH
- peptidy krev MeSH
- prokolagen krev MeSH
- remodelace kosti * fyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- přehledy MeSH
PURPOSE: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. METHODS: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. RESULTS: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. CONCLUSION: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.
Biochemistry Department College of Science King Saud University Riyadh 11451 Kingdom of Saudi Arabia
Cedars Sinai Medical Center OMC Clinical Research Center Beverly Hills CA 90211 USA
Centre for Metabolic Bone Diseases University of Sheffield Sheffield UK
Clinical Biochemistry Department General Hospital of Lamia 35100 Lamia Greece
Clinical Biochemistry Department KAT General Hospital Kifissia Athens Greece
Department of Clinical Biochemistry and Bone Metabolism Klatovska Hospital Klatovy Czech Republic
Department of Clinical Biochemistry Rigshospitalet Copenhagen Denmark
Department of Endocrinology Ghent University Hospital Ghent Belgium
Diaverum AB Hyllie Boulevard 53 215 37 Malmö Sweden
Division d'Epidémiologie Santé Publique Et Economie de La Santé Université de Liège Liège Belgium
Faculdade de Farmácia Universidade de Lisboa Avenida Professor Gama Pinto 1649 003 Lisbon Portugal
Faculty of Health Care Studies University of West Bohemia Pilsen Czech Republic
Faculty of Medicine University of Novi Sad Novi Sad Serbia
Faculty of Pharmaceutical Sciences Hokuriku University Kanazawa Japan
Geneva University Hospitals Faculty of Medicine Geneva Switzerland
Icelandic Medicines Agency Vínlandsleið 14 113 Reykjavík Iceland
INSERM UMR 1033 Université Claude Bernard Lyon1 Hôpital E Herriot 69437 Lyon France
Laboratory of Experimental Biochemistry IRCCS Ospedale Galeazzi Sant'Ambrogio Milan Italy
MRC Lifecourse Epidemiology Centre University of Southampton Southampton UK
PathWest Laboratory Medicine WA Murdoch WA6150 Australia
Scientific Office Austrian Medicines and Medical Devices Agency Vienna Austria
Spanish Agency for Medicines and Medical Devices Madrid Spain
Translational Research Centre Rigshospitalet Copenhagen Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016227
- 003
- CZ-PrNML
- 005
- 20250731091624.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00198-025-07422-3 $2 doi
- 035 __
- $a (PubMed)40152990
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bhattoa, Harjit Pal $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei Blvd. 98, 4032, Debrecen, Hungary. harjit@med.unideb.hu $1 https://orcid.org/0000000249090065
- 245 10
- $a Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) / $c HP. Bhattoa, S. Vasikaran, I. Trifonidi, G. Kapoula, G. Lombardi, NR. Jørgensen, R. Pikner, M. Miura, R. Chapurlat, M. Hiligsmann, M. Haarhaus, P. Evenepoel, HS. Jørgensen, M. Herrmann, JM. Kaufman, P. Clark, Ş. Tuzun, N. Al-Daghri, S. Silverman, MS. Alokail, S. Ormarsdóttir, MCP. Yerro, R. Matijevic, A. Laslop, MMC. da Silva Rosa, L. Zakraoui, N. Burlet, E. McCloskey, NC. Harvey, RP. Radermecker, M. Fusaro, C. Torre, JA. Kanis, R. Rizzoli, JY. Reginster, K. Makris, E. Cavalier
- 520 9_
- $a PURPOSE: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. METHODS: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. RESULTS: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. CONCLUSION: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 12
- $a remodelace kosti $x fyziologie $7 D016723
- 650 _2
- $a osteoporotické fraktury $x prevence a kontrola $x etiologie $7 D058866
- 650 12
- $a osteoporóza $x diagnóza $x patofyziologie $x farmakoterapie $x krev $x terapie $7 D010024
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a prokolagen $x krev $7 D011347
- 650 _2
- $a hodnocení rizik $x metody $7 D018570
- 650 _2
- $a kolagen typu I $x krev $7 D024042
- 650 _2
- $a inhibitory kostní resorpce $x terapeutické užití $7 D050071
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a konsensus $7 D032921
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a konsensus - konference $7 D016446
- 700 1_
- $a Vasikaran, Samuel $u PathWest Laboratory Medicine WA, Murdoch, WA6150, Australia $1 https://orcid.org/0000000208313031
- 700 1_
- $a Trifonidi, Ioulia $u Clinical Biochemistry Department-KAT General Hospital, Kifissia, Athens, Greece $u Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, University of Athens, Athens, Greece $1 https://orcid.org/0000000239998459
- 700 1_
- $a Kapoula, Georgia $u Clinical Biochemistry Department, General Hospital of Lamia, 35100, Lamia, Greece $1 https://orcid.org/0000000267140812
- 700 1_
- $a Lombardi, Giovanni $u Laboratory of Experimental Biochemistry, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy $u Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, Poznań, Poland $1 https://orcid.org/000000028365985X
- 700 1_
- $a Jørgensen, Niklas Rye $u Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $u Translational Research Centre, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/0000000196245210
- 700 1_
- $a Pikner, Richard $u Department of Clinical Biochemistry and Bone Metabolism, Klatovska Hospital, Klatovy, Czech Republic $u Department of Clinical Biochemistry and Haematology, Faculty of Medicine Pilsen, Charles University Prague, Pilsen, Czech Republic $u Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic $1 https://orcid.org/0000000206338876
- 700 1_
- $a Miura, Masakazu $u Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan $1 https://orcid.org/0000000156853924
- 700 1_
- $a Chapurlat, Roland $u INSERM UMR 1033, Université Claude Bernard-Lyon1, Hôpital E Herriot, 69437, Lyon, France $1 https://orcid.org/0000000182146385
- 700 1_
- $a Hiligsmann, Mickael $u Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands $1 https://orcid.org/0000000342749258
- 700 1_
- $a Haarhaus, Mathias $u Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, 141 86, Stockholm, Sweden $u Diaverum AB, Hyllie Boulevard 53, 215 37, Malmö, Sweden $1 https://orcid.org/0000000182746356
- 700 1_
- $a Evenepoel, Pieter $u University Hospitals Leuven and Laboratory of Nephrology, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Louvain, Belgium $1 https://orcid.org/0000000207974321
- 700 1_
- $a Jørgensen, Hanne Skou $u Department of Clinical Medicine - Department of Medicine and Nephrology, Aarhus University, Aarhus, Denmark $u Department of Clinical Medicine and Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark $u Department of Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KatholiekeUniversitet Leuven (KU Leuven), Louvain, Belgium $1 https://orcid.org/0000000208812615
- 700 1_
- $a Herrmann, Markus $u Clinical Institute of Medical and Chemical Diagnostics, Medical University of Graz, Auenbruggerplatz 15 /1, 8036, Graz, Austria $1 https://orcid.org/0000000235599899
- 700 1_
- $a Kaufman, Jean-Marc $u Department of Endocrinology, Ghent University Hospital, Ghent, Belgium $1 https://orcid.org/0000000214006812
- 700 1_
- $a Clark, Patricia $u Clinical Epidemiology Unit, Faculty of Medicina UNAM, Hospital Infantil Federico Gómez, Mexico City, Mexico $1 https://orcid.org/0000000179815357
- 700 1_
- $a Tuzun, Şansın $u Department of Physical Medicine and Rehabilitation, Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey $1 https://orcid.org/0000000233002286
- 700 1_
- $a Al-Daghri, Nasser $u Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Kingdom of Saudi Arabia $1 https://orcid.org/0000000154721725
- 700 1_
- $a Silverman, Stuart $u Cedars-Sinai Medical Center, OMC Clinical Research Center, Beverly Hills, CA, 90211, USA $1 https://orcid.org/0000000253131018
- 700 1_
- $a Alokail, Majed S $u Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Kingdom of Saudi Arabia
- 700 1_
- $a Ormarsdóttir, Sif $u Icelandic Medicines Agency, Vínlandsleið 14, 113, Reykjavík, Iceland
- 700 1_
- $a Yerro, María Concepción Prieto $u Spanish Agency for Medicines and Medical Devices, Madrid, Spain
- 700 1_
- $a Matijevic, Radmila $u Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia $1 https://orcid.org/0000000249939399
- 700 1_
- $a Laslop, Andrea $u Scientific Office, Austrian Medicines and Medical Devices Agency, Vienna, Austria $1 https://orcid.org/0009000927073959
- 700 1_
- $a da Silva Rosa, Mario Miguel Coelho $u Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal $1 https://orcid.org/0000000331582106
- 700 1_
- $a Zakraoui, Leith $u University of Tunis El Manar, Tunis, Tunisia $1 https://orcid.org/0000000192765892
- 700 1_
- $a Burlet, Nansa $u Division d'Epidémiologie, Santé Publique Et Economie de La Santé, Université de Liège, Liège, Belgium
- 700 1_
- $a McCloskey, Eugene $u Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK $1 https://orcid.org/0000000301778140
- 700 1_
- $a Harvey, Nicholas C $u MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK $u NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK $1 https://orcid.org/0000000281942512
- 700 1_
- $a Radermecker, Régis P $u CHU de Liège and Centre de Recherche Intégré Sur Les Médicaments (CIRM), Department of Clinical Pharmacology, University of Liège, Domaine du Sart-Tilman, B-4000, Liège, Belgium $1 https://orcid.org/0000000228668171
- 700 1_
- $a Fusaro, Maria $u Institute of Clinical Physiology, 56124, Pisa and Department of Medicine, National Research Council, University of Padova, Padua, Italy $1 https://orcid.org/0000000194784851
- 700 1_
- $a Torre, Carla $u Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003, Lisbon, Portugal $u Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines of the University of Lisbon (iMed.ULisboa), Lisbon, Portugal $1 https://orcid.org/0000000255429993
- 700 1_
- $a Kanis, John A $u Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK $1 https://orcid.org/0000000231294326
- 700 1_
- $a Rizzoli, René $u Geneva University Hospitals, Faculty of Medicine, Geneva, Switzerland $1 https://orcid.org/000000021537422X $7 xx0182608
- 700 1_
- $a Reginster, Jean-Yves $u Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Kingdom of Saudi Arabia $1 https://orcid.org/000000016290752X $7 nlk20040158038
- 700 1_
- $a Makris, Konstantinos $u Clinical Biochemistry Department-KAT General Hospital, Kifissia, Athens, Greece $u Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, University of Athens, Athens, Greece $1 https://orcid.org/0000000278969028
- 700 1_
- $a Cavalier, Etienne $u CHU de Liège and Centre de Recherche Intégré Sur Les Médicaments (CIRM), Department of Clinical Chemistry, University of Liège, Domaine du Sart-Tilman, B-4000, Liège, Belgium $1 https://orcid.org/0000000309472226
- 773 0_
- $w MED00003659 $t Osteoporosis international $x 1433-2965 $g Roč. 36, č. 4 (2025), s. 579-608
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40152990 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091618 $b ABA008
- 999 __
- $a ok $b bmc $g 2366815 $s 1253352
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 36 $c 4 $d 579-608 $e 20250328 $i 1433-2965 $m Osteoporosis international $n Osteoporos Int $x MED00003659
- LZP __
- $a Pubmed-20250708
